全球去势抗性前列腺癌市场按治疗类型、药物类别、给药途径、分销管道和地区划分

2025 年全球去势抗性前列腺癌市场规模估计为 106.6 亿美元，预计到 2032 年将达到 192.6 亿美元，2025 年至 2032 年的复合年增长率为 8.8%。

市场占有率。

全球去势抗性前列腺癌市场的成长是由世界范围内前列腺癌患病率的上升所推动的。摄护腺癌是男性最常见的癌症之一。根据美国癌症协会2020年的资料，美国报告了约191,930例前列腺癌新病例。当癌症儘管接受了降低睪固酮水平或阻止其作用的药物或手术治疗，但仍扩散并开始生长时，就称为去势抗性前列腺癌 (CRPC)。目前，CRPC 的治疗方法包括化疗、免疫疗法和放射线治疗。然而，抗药性的产生仍然是有效治疗晚期前列腺癌的重大挑战。正在进行的针对新药物标靶和治疗方法的研究可能有助于克服抗治疗性并改善 CRPC 患者的治疗效果。

市场动态：

全球去势抗性前列腺癌市场的成长是由老年人口的增加所推动的，老年人口更容易罹患摄护腺癌。根据联合国《2020年世界人口展望》资料，65岁以上人口预计将从2020年的7.03亿增加到2050年的15亿。人们对前列腺癌的认识和筛检率的提高也刺激了前列腺癌的早期发现，从而推动了市场的成长。然而，免疫疗法和标靶治疗方案的高治疗成本可能会阻碍市场成长。正在进行的旨在克服抗药性的新机制的研究可能会为市场相关人员提供良好的机会。开发价格合理的生物相似药有助于降低治疗成本。

本研究的主要特点

• 本报告对全球去势抗性前列腺癌市场进行了详细分析，并提供了预测期（2025-2032 年）的市场规模和复合年增长率，以 2024 年为基准年。
• 它还强调了各个领域的潜在商机并解释了该市场的有吸引力的投资提案矩阵。
• 它还提供了对市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景以及主要企业采用的竞争策略的重要见解。
• 它根据公司亮点、产品系列、关键亮点、财务表现和策略等参数，介绍了全球去势抗性前列腺癌市场的主要企业概况。
• 本报告的见解将使负责人和公司经营团队能够就未来的产品发布、类型升级、市场扩张和行销策略做出明智的决策。
• 全球去势抗性前列腺癌市场报告涉及该行业的各个相关人员，例如投资者、供应商、产品製造商、经销商、新进业者和金融分析师。
• 相关人员可以透过用于分析全球去势抗性前列腺癌市场的各种策略矩阵来促进决策。

目录

第一章 调查目的与前提条件

• 研究目标
• 先决条件
• 简称

第二章 市场展望

• 报告描述
  • 市场定义和范围
• 执行摘要
• Coherent Opportunity Map（COM）

第三章市场动态、法规与趋势分析

• 市场动态
  • 驱动程式
  • 限制因素
  • 机会
• 影响分析
• 市场趋势
• 主要进展
• 监管情景
• 收购和合作场景
• 资金筹措和投资
• PEST分析
• 波特的分析

4. 全球去势抗性前列腺癌市场：COVID-19 疫情的影响

• 整体影响
• 政府倡议
• COVID-19 市场影响

第 5 章 全球去势抗性前列腺癌市场依治疗类型划分（2020-2032 年）

• 荷尔蒙疗法
• 免疫疗法
• 化疗
• 放射治疗

第 6 章 全球去势抗性前列腺癌市场按药物类别划分（2020-2032 年）

• 抗癌药物
• 非类固醇抗雄激素
• 皮质类固醇
• 微管抑制剂
• 其他的

7. 全球去势抗性前列腺癌市场按通路划分（2020-2032 年）

• 院内药房
• 零售药局
• 网路药局

第 8 章 全球去势抗性前列腺癌市场依给药途径划分（2020-2032 年）

• 口服
• 注射

9. 全球去势抗性前列腺癌市场（按地区划分） (2020-2032)

• 北美洲
• 拉丁美洲
• 欧洲
• 亚太地区
• 中东
• 非洲

第十章 竞争格局

• 公司简介
  • Trelleborg Sealing Solutions
  • Freudenberg Group
  • Parker Hannifin Corp
  • Saint-Gobain
  • Bal Seal Engineering, Inc.
  • Flexan
  • Marco Rubber &Plastics
  • Morgan Polymer Seals
  • Minnesota Rubber and Plastics
  • Precision Associates, Inc.
  • IDEX Health &Science LLC
  • Apple Rubber Products
  • Technetics Group
  • Sterne SAS
  • ResMed
  • West Pharmaceutical Services, Inc.

第 11 章 分析师建议

• 命运之轮
• 分析师观点
• Coherent Opportunity Map（COM）

第 12 章参考文献与调查方法

• 参考
• 调查方法

Global Castrate Resistant Prostate Cancer Market is estimated to be valued at USD 10.66 Bn in 2025 and is expected to reach USD 19.26 Bn by 2032, growing at a compound annual growth rate (CAGR) of 8.8% from 2025 to 2032.

Figure. Castrate Resistant Prostate Cancer Market Share (%), By Region 2025

Global castrate resistant prostate cancer market growth is driven by rising prevalence of prostate cancer worldwide. Prostate cancer is one of the commonly occurring cancers among men. According to the data from American Cancer Society in 2020, around 191,930 new cases of prostate cancer were reported in the U.S. Once the cancer has metastasized and started growing despite medical or surgical therapy to reduce testosterone levels or block its action, it is termed as castrate resistant prostate cancer (CRPC). Currently available treatment options for CRPC include chemotherapy, immunotherapy, radiation therapy, and others. However, development of resistance remains a major challenge in effectively managing this advanced stage of prostate cancer. Ongoing research for novel drug targets and therapeutic approaches can overcome treatment resistance and improve patient outcomes in CRPC.

Market Dynamics:

Global castrate resistant prostate cancer market growth is driven by rising geriatric population susceptible to developing prostate cancer. According to the data from UN World Population Prospects 2020, the number of people aged 65 years or above is projected to grow from 703 million in 2020 to 1.5 billion in 2050 globally. Increasing awareness and screening rates have also augmented the early detection of prostate cancer, thus, driving the market growth. However, high treatment costs associated with immunotherapy and targeted therapy regimens can hamper the market growth. Ongoing research to develop novel mechanisms for overcoming drug resistance can offer promising opportunities for market players. Development of affordable biosimilars can reduce treatment costs.

Key Features of the Study:

• This report provides in-depth analysis of the global castrate resistant prostate cancer market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global castrate resistant prostate cancer market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Johnson & Johnson, Astellas Pharma, Sanofi, Dendreon, Bayer, and others
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global castrate resistant prostate cancer market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global castrate resistant prostate cancer market

Detailed Segmentation-

• By Therapy Type
  • Hormonal Therapy
  • Immunotherapy
  • Chemotherapy
  • Radiotherapy
• By Drug Class
  • Antineoplastic
  • Non-steroidal Antiandrogen
  • Corticosteroids
  • Microtubule Inhibitor
  • Others
• By Route of Administration
  • Oral
  • Injectable
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
  • Trelleborg Sealing Solutions
  • Freudenberg Group
  • Parker Hannifin Corp
  • Saint-Gobain
  • Bal Seal Engineering, Inc.
  • Flexan
  • Marco Rubber & Plastics
  • Morgan Polymer Seals
  • Minnesota Rubber and Plastics
  • Precision Associates, Inc.
  • IDEX Health & Science LLC
  • Apple Rubber Products
  • Technetics Group
  • Sterne S.A.S.
  • ResMed
  • West Pharmaceutical Services, Inc.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Therapy Type
  • Market Snapshot, By Drug Class
  • Market Snapshot, By Route of Administration
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Opportunities
• Impact Analysis
• Market Trends
• Key Developments
• Regulatory Scenario
• Acquisitions and Partnerships Scenario
• Funding and Investments
• PEST Analysis
• Porter's Analysis

4. Global Castrate Resistant Prostate Cancer Market- Impact of Coronavirus (COVID-19) Pandemic

• Overall Impact
• Government Initiatives
• COVID-19 Impact on the Market

5. Global Castrate Resistant Prostate Cancer Market, By Therapy Type, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Hormonal Therapy
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Immunotherapy
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Chemotherapy
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Radiotherapy
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Castrate Resistant Prostate Cancer Market, By Drug Class, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Antineoplastic
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Non-steroidal Antiandrogen
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Corticosteroids
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Microtubule Inhibitor
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Castrate Resistant Prostate Cancer Market, By Distribution Channel, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Hospital Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Retail Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Online Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Castrate Resistant Prostate Cancer Market, By Route of Administration, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Oral
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Injectable
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

9. Global Castrate Resistant Prostate Cancer Market, By Region, 2020 - 2032, (USDBn)

• Introduction
  • Market Share Analysis, By Region, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, For Region, 2021-2032
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020 - 2032, (USD Bn)
    • North Africa
    • Central Africa
    • South Africa

10. Competitive Landscape

• Company Profiles
  • Trelleborg Sealing Solutions
    • Company Highlights
    • Method Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Freudenberg Group
    • Company Highlights
    • Method Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Parker Hannifin Corp
    • Company Highlights
    • Method Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Saint-Gobain
  • Bal Seal Engineering, Inc.
  • Flexan
  • Marco Rubber & Plastics
  • Morgan Polymer Seals
  • Minnesota Rubber and Plastics
  • Precision Associates, Inc.
  • IDEX Health & Science LLC
  • Apple Rubber Products
  • Technetics Group
  • Sterne S.A.S.
  • ResMed
  • West Pharmaceutical Services, Inc.

11. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

12. References and Research Methodology

• References
• Research Methodology
• About Us and Sales Contact